Flightpath Biosciences Rebrands, Unveils New Logo

Biotech company Flightpath Biosciences has introduced a new corporate identity featuring a new logo and website.

The rebranding highlights the American firm's ongoing growth and is part of efforts to attract investors, which also includes participation in upcoming events like the J.P. Morgan Healthcare Conference in January next year.

The new branding aligns with the announcement of a significant breakthrough with the licensing of the company's latest drug candidate named "FP530" (or "Formibactin A"), a potential antibiotic reportedly rediscovered by Flightpath's co-founder Kim Lewis, PhD, who is also the head of Northeastern University’s Antimicrobial Drug Discovery Center.

"Flightpath has the unusual opportunity to study this drug with potential for impact in multiple biological compartments to rid the body of underlying pathogenic bacteria, while not destroying the symbiotic flora that is so important to human health," says Dr. Lewis.

The Detroit, Michigan-headquartered firm is in the process of developing a proprietary "Targeted Bacterial Deletion" platform, a type of treatment designed to eliminate the bacteria responsible for inflammation and tissue damage associated with diseases such as cancer, neuroborreliosis, inflammatory bowel disease, and women’s health conditions – all while aiming to keep the healthy microbiome intact.

"We believe that by targeting the bacteria driving the early disease process, within a critical window of opportunity, we can transform treatment and outcomes for patients suffering from a range of complex diseases," states Matt Tindall, executive chairman and CEO of Flightpath Biosciences.

Source: Flightpath Biosciences